Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00380211 | Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults | PHASE3 | COMPLETED | 660 | — | — | Sep 1, 2006 | Nov 1, 2006 | Oct 7, 2016 | 6 | United States |
| NCT00197288 | Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines | PHASE3 | COMPLETED | 1,847 | — | — | Oct 1, 2005 | Jun 1, 2006 | Jan 18, 2017 | 15 | United States |
| NCT00197223 | Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine | PHASE3 | COMPLETED | 6,213 | — | — | Sep 1, 2005 | May 1, 2006 | Mar 23, 2017 | 1 | Czechia |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine (A/H3N2, A/H1N1, and B strains) | BIOLOGICAL | - |
| Fluarix | BIOLOGICAL | - |
| Influenza | BIOLOGICAL | - |
| Influenza vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Male or female adults (≥18 yrs) * Stable health status * Provide informed consent * Access to direct phone service (NOT a pay phone or a common-use phone service) * Eligible females must have a negative pregnancy test Exclusion Criteria: * Febrile illness (\>38.0°C oral temp...